Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.

Innovation Building with BioEscalator, EnaraBio and Boehringer Ingelheim logos

Enara Bio, an SV Health backed start-up, was founded in 2016 using technology developed at the Francis Crick Institute, London. The company joined the BioEscalator, Oxford University’s biotech incubator, in 2018 as Ervaxx with five employees and has since developed two proprietary platforms EDAPT™ and Dark Antigen™, rebranded as Enara Bio and grown the team to twenty-seven. Enara Bio has utilised its strong relationship with Oxford academics, including immunopeptidomics expert Dr Nicola Ternette and Vaccitech’s Professor Adrian Hill, both of the Nuffield Department of Medicine, to develop its innovative technologies.  It will now utilise Boehringer’s wealth of big pharma development resources to help drive discoveries further towards the clinic.

The partnership will provide additional funding to advance Dark Antigen research along with further independent validation of Enara’s novel EDAPT™ platform.

We’re excited to be partnered with an innovation-led company that has built considerable expertise in cancer vaccines and immune-oncology - Kevin Pojasek, CEO Enara Bio

Read the full story on the BioEscalator website

Similar stories

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.